Literature DB >> 11342973

Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.

I Hara1, H Miyake, S Hara, S Arakawa, S Kamidono.   

Abstract

PURPOSE: We determined whether expression levels of matrix metalloproteinase (MMP)-2, MMP-9, membrane-type MMP-1 (MT1-MMP), tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 messenger (m) RNA in superficial transitional cell carcinoma of the bladder may be used as predictors of tumor recurrence.
MATERIALS AND METHODS: Total RNA was extracted from 51 superficial transitional cell carcinomas of the bladder, and expression levels of MMP-2, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 messenger mRNA in these specimens were measured by Northern blot analysis. Results were evaluated in regard to tumor recurrence.
RESULTS: Mean MMP-9 and TIMP-2 mRNA expression in the tumors of patients with recurrence were 2.5 and 3-fold higher, respectively, than in those of patients without recurrence despite no significant differences in MMP-2, MT1-MMP or TIMP-1 expression. The recurrence-free survival rate of patients with elevated MMP-9 and TIMP-2 mRNA expression was significantly lower than that of patients with normal MMP-9 and TIMP-2 expression, respectively. In addition, Cox's multivariate analysis revealed that elevated MMP-9 and TIMP-2 were strongly associated with a high incidence of intravesical recurrence of superficial bladder cancer.
CONCLUSIONS: These results indicate that MMP-9 and TIMP-2 are strongly expressed in the tumors of patients with recurrence compared with those without recurrence and elevated MMP-9 and TIMP-2 may be used as predictors of recurrence in patients with superficial transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342973

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

2.  Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer.

Authors:  Özgür Efiloğlu; Banu İşbilen Başok; Turgay Turan; Tuncay Toprak; Bülent Erol; Turhan Çaşkurlu; Asıf Yıldırım
Journal:  Turk J Urol       Date:  2020-02-07

Review 3.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

4.  Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.

Authors:  R Singh; A Mandhani; V Agrawal; Minal Garg
Journal:  Cancer Microenviron       Date:  2018-01-18

5.  Clinical significance and prognostic value of S100A4 and matrix metalloproteinase-14 in patients with organ-confined bladder cancer.

Authors:  Yuji Sagara; Yasuyoshi Miyata; Takahisa Iwata; Shigeru Kanda; Tomayoshi Hayashi; Hideki Sakai; Hiroshi Kanetake
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

Review 6.  The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.

Authors:  Paulina Wigner; Radosław Grębowski; Michał Bijak; Joanna Saluk-Bijak; Janusz Szemraj
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 7.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

8.  Matrix Metalloproteinases and Bladder Cancer: What is New?

Authors:  O Rodriguez Faba; J Palou-Redorta; J M Fernández-Gómez; F Algaba; N Eiró; H Villavicencio; F J Vizoso
Journal:  ISRN Urol       Date:  2012-07-17

9.  Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma.

Authors:  M J Wallard; C J Pennington; A Veerakumarasivam; G Burtt; I G Mills; A Warren; H Y Leung; G Murphy; D R Edwards; D E Neal; J D Kelly
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

10.  High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.

Authors:  Tobias Benoit; Etienne X Keller; Pirmin Wolfsgruber; Thomas Hermanns; Michele Günthart; Irina Banzola; Tullio Sulser; Maurizio Provenzano; Cédric Poyet
Journal:  Med Sci Monit       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.